Publication date: Jul 22, 2025
In May 2023, the first respiratory syncytial virus (RSV) vaccines were approved for adults 60 years and older in the United States. In April 2024, we fielded a survey in the state of South Dakota to investigate RSV vaccine uptake among this vulnerable population group. The survey measured RSV vaccine uptake, uptake of other vaccines, and other social and political variables associated with vaccine uptake. We analyzed the data using path analysis in SAS statistical software. The sample consisted of 376 participants 60 years and older. Of those, 33 % received the RSV vaccine. Path analysis results showed direct associations between RSV vaccine uptake and COVID-19 vaccine uptake (standardized effect of 0. 2548, p
| Concepts | Keywords |
|---|---|
| April | Partisan self-identification |
| Dakota | Path analysis |
| Seniors | RSV vaccine uptake |
| Virus | Vulnerable populations |